New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
16:13 EDTTSROTESARO reports Q2 EPS ($1.03), consensus (87c)
TESARO anticipates achieving the following key objectives during the second half of 2014: Submit the oral rolapitant New Drug Application to the FDA in approximately six weeks; Initiate a clinical trial of IV rolapitant to support the planned future NDA submission for registration following regulatory approval of oral rolapitant; Continue to advance the Phase 3 NOVA trial of niraparib as a maintenance therapy for patients with ovarian cancer and the Phase 3 BRAVO trial of niraparib in breast cancer patients with germline BRCA mutations; Advance the TSR-011 controlled release formulation work and further evaluate the clinical activity of a fractionated dose of TSR-011 in ALK-positive and TRK-positive patients.
News For TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2015
11:15 EDTTSROTESARO participates in a conference call with Leerink
Analyst Fernandez holds a conference call with CEO Moulder and COO Hedley to discuss the upcoming launch dynamics for Varubi, data read-outs for Niraparib and the development plans for the company's immuno-oncology portfolio on October 15 at 1 pm.
October 1, 2015
07:31 EDTTSROLeerink to hold a roundtable
Subscribe for More Information
September 29, 2015
10:09 EDTTSROHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use